Globe Newswire Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE...\n more…
Ticker Report Candriam S.C.A. decreased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.0% during the 2nd quarter, according to the company in its most recent disclosure with the...\n more…
Ticker Report Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading on Wednesday. Stock investors bought 4,063 put options on the stock. This represents an increase of...\n more…
Ticker Report Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)s stock had its "outperform" rating reiterated by analysts at Royal Bank of Canada in a note issued to investors on Tuesday, Benzinga...\n more…
Ticker Report Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been assigned an average rating of "Buy" from the nine ratings firms that are presently covering the stock, MarketBeat...\n more…